Susana Braga

Dr. Susana Braga

QOONA & LAQV/REQUIMTE, Department of Chemistry, University of Aveiro
+1
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2013 in Organometallics
Verified
Journal Article
Closed access
Susana BragaSusana Braga
Susana Braga
Artur M. S. SilvaArtur M. S. Silva
Artur M. S. Silva

24 June 2021 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
Javad Sharifi-RadJavad Sharifi-Rad
Javad Sharifi-Rad
EQE. Cristina Quispe
E. Cristina Quispe
Monica BUTNARIUMonica BUTNARIU
Monica BUTNARIU
LRLia Sanda Rotariu
Lia Sanda Rotariu
Oksana SytarOksana Sytar
Oksana Sytar
Daniela CalinaDaniela Calina
Daniela Calina
The study describes the current state of knowledge on nanotechnology and its utilization in medicine. The focus in this manuscript was on the properties, usage safety, and potentially valuable applications of chitosan-based nanomaterials. Chitosan nanoparticles have high importance in nanomedicine, biomedical engineering, discovery and development of new drugs. The manuscript reviewed the new studies regarding the use of chitosan-based nanoparticles for creating new release systems with improved bioavailability, increased specificity and sensitivity, and reduced pharmacological toxicity of drugs. Nowadays, effective cancer treatment is a global problem, and recent advances in nanomedicine are of great importance. Special attention was put on the application of chitosan nanoparticles in developing new system for anticancer drug delivery. Pre-clinical and clinical studies support the use of chitosan-based nanoparticles in nanomedicine. This manuscript overviews the last progresses regarding the utilization, stability, and bioavailability of drug nanoencapsulation with chitosan and their safety.

28 November 2019 in Biomolecules
Verified
Journal Article
Open access
PDF file
Susana BragaSusana Braga
Susana Braga
Cyclodextrins, since their discovery in the late 19th century, were mainly regarded as excipients. Nevertheless, developments in cyclodextrin research have shown that some of these hosts can capture and include biomolecules, highlighting fatty acids and cholesterol, which implies that they are not inert and that their action may be used in specific medicinal purposes. The present review, centered on literature reports from the year 2000 until the present day, presents a comprehensive description of the known biological activities of cyclodextrins and their implications for medicinal applications. The paper is divided into two main sections, one devoted to the properties and applications of cyclodextrins as active pharmaceutical ingredients in a variety of pathologies, from infectious ailments to cardiovascular dysfunctions and metabolic diseases. The second section is dedicated to the use of cyclodextrins in a range of biomedical technologies.

1 February 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JBJéssica S. Barbosa
Jéssica S. Barbosa
Filipe Almeida PazFilipe Almeida Paz
Filipe Almeida Paz
Susana BragaSusana Braga
Susana Braga

1 December 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Susana BragaSusana Braga
Susana Braga

24 January 2013 in CrystEngComm
Verified
Journal Article
Closed access
PDF file
Ana RamosAna Ramos
Ana Ramos
TBTeresa Braga
Teresa Braga
PSPatrícia Silva
Patrícia Silva
JFJosé A. Fernandes
José A. Fernandes
PRPaulo Ribeiro-Claro
Paulo Ribeiro-Claro
Susana BragaSusana Braga
Susana Braga
β-Cyclodextrin (βCD) inclusion compounds of chloramphenicol in the solid-state were prepared via two different procedures, co-crystallisation from aqueous solution and the solvent-free method of co-grinding. Chloramphenicol inclusion into permethylated βCD (TRIMEB) was also performed by co-dissolution in ethanol. The co-crystallisation procedure was the best for preparing chloramphenicol·βCD in 1 : 1 stoichiometry in high purity, while with the co-grinding treatment and the same starting proportion, a complete inclusion was not achieved. Microcrystals of chloramphenicol·βCD inclusion compound presented polymorphism, crystallising simultaneously in the triclinic P1 or monoclinic C2 space groups. Only crystals of the latter were suitable for single-crystal diffraction and data for the guest atoms was comprised of a smeared-out electron cloud, so theoretical calculations were used to propose their plausible geometry and location inside the host molecules. The co-grinding procedure curbed polymorphism and allowed the preparation of chloramphenicol·βCD in the amorphous state; chloramphenicol·TRIMEB prepared by co-dissolution of the components in a 1 : 1 proportion was also an amorphous material. The influence of inclusion with βCD and TRIMEB on the antimicrobial performance of chloramphenicol was evaluated, and both inclusion compounds demonstrated selective action against Enterococcus faecalis strains ATCC 29212 and A33562 and Listeria monocytogenes ATCC 7644. Chloramphenicol·TRIMEB also had higher activity against the E. faecalis strains A35906, 9308 and E4856 and against Listeria inocua.